Guidelines address myocarditis and other types of myocardial involvement, postacute sequelae of SARS-CoV-2, and return to exercise
Sotrovimab May Prevent Progression to Severe COVID-19
Risk for all-cause hospitalization or death through day 29 reduced with sotrovimab versus placebo for circulating variants at the time of the study